NASDAQ:CDXC ChromaDex (CDXC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About ChromaDex Stock (NASDAQ:CDXC) 30 days 90 days 365 days Advanced Chart Remove Ads Get ChromaDex alerts:Sign Up Key Stats Today's Range N/A50-Day Range$5.26▼$8.5552-Week Range N/AVolume554,788 shsAverage Volume702,590 shsMarket Capitalization$611.50 millionP/E Ratio787.29Dividend YieldN/APrice Target$9.03Consensus RatingBuy Company OverviewChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Read More… Remove Ads ChromaDex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreCDXC MarketRank™: ChromaDex scored higher than 79% of companies evaluated by MarketBeat, and ranked 172nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChromaDex has only been the subject of 2 research reports in the past 90 days.Read more about ChromaDex's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth200.00% Earnings GrowthEarnings for ChromaDex are expected to grow by 200.00% in the coming year, from $0.04 to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChromaDex is 787.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.03.Price to Earnings Ratio vs. SectorThe P/E ratio of ChromaDex is 787.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.20.Read more about ChromaDex's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.29% of the float of ChromaDex has been sold short.Short Interest Ratio / Days to CoverChromaDex has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ChromaDex has recently decreased by 3.65%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChromaDex does not currently pay a dividend.Dividend GrowthChromaDex does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.85 Percentage of Shares Shorted4.29% of the float of ChromaDex has been sold short.Short Interest Ratio / Days to CoverChromaDex has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ChromaDex has recently decreased by 3.65%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ChromaDex this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CDXC on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows1 people have added ChromaDex to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ChromaDex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.64% of the stock of ChromaDex is held by insiders.Percentage Held by InstitutionsOnly 15.41% of the stock of ChromaDex is held by institutions.Read more about ChromaDex's insider trading history. Receive CDXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXC Stock News HeadlinesChromaDex (NASDAQ:CDXC) Now Covered by Analysts at StockNews.comMarch 29, 2025 | americanbankingnews.comWhy ChromaDex Corp (CDXC) Is Surging In 2025?March 25, 2025 | msn.comTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.April 4, 2025 | American Alternative (Ad)ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision ScienceMarch 19, 2025 | businesswire.comChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025March 13, 2025 | businesswire.comChromaDex to Present at the 37th Annual Roth ConferenceMarch 11, 2025 | businesswire.comChromaDex price target raised to $11 from $8 at H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comChromaDex Capitalizes On Longevity Boom, But Valuation Remains HighMarch 6, 2025 | seekingalpha.comSee More Headlines CDXC Stock Analysis - Frequently Asked Questions How were ChromaDex's earnings last quarter? ChromaDex Co. (NASDAQ:CDXC) announced its earnings results on Thursday, October, 31st. The company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.02. The business had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a trailing twelve-month return on equity of 4.85%. How do I buy shares of ChromaDex? Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ChromaDex own? Based on aggregate information from My MarketBeat watchlists, some other companies that ChromaDex investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings10/31/2024Today4/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDXC CIK1386570 Webwww.chromadex.com Phone(310) 388-6706Fax949-419-0294Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$9.03 High Stock Price Target$11.00 Low Stock Price Target$8.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.10 Trailing P/E Ratio787.29 Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,940,000.00 Net Margins1.62% Pretax Margin1.62% Return on Equity4.85% Return on Assets2.70% Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio2.35 Sales & Book Value Annual Sales$99.60 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / BookN/AMiscellaneous Outstanding Shares77,750,000Free Float69,020,000Market Cap$611.50 million OptionableOptionable Beta2.21 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (NASDAQ:CDXC) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ChromaDex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.